| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2020: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2019: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2018: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
|
|---|
| Outline of Final Research Achievements |
We investigated the genetic alterations of ovarian mutinous carcinoma (MC), borderline tumor (MBT) and benign cyst adenoma (MA) using surgically specimens. The sequencing analyses revealed frequent BRAF mutations in MBT, but not MC or MA, while KRAS mutations were frequent in MC, less frequent in MBT and none in MA. These findings indicate that BRAF mutation is involved in the development of MBT while MBT with such mutations has low potential to develop MC. In contrast, KRAS mutation is a key factor to the development of MC from MBT.
|
